Miho Katagi
Founder/Director of Smiley
Tokyo, Japan

2019 IGCS Distinguished Advocacy Award授賞スピーチ動画
In 2004, at 30 years old, Miho Katagi was diagnosed with ovarian cancer (Mucinous, Stage Ia). At the time, this mother of a 2-year-old son knew nothing about ovarian cancer and felt anxiety every day. During this time, she found support and encouragement from other ovarian cancer patients she met online.
In 2006, when she found out that there were few anti-cancer drugs available and approved in Japan to effectively treat ovarian cancer patients, she decided to form the first and only patient support group specific for ovarian cancer patients in Japan. And, since not being able to receive treatment will take away a patient’s smile, she called the support group “Smiley,” wanting to give patients reasons to feel more at ease and to smile.
Because they considered the time lag between drug approval in other countries and approval for use in Japan a severe disadvantage for Japanese patients, the group appealed to the government to reduce this so-called “drug lag” as a serious social problem/issue. They lobbied and even appealed to the mass media to solve this social problem and eliminate/reduce the disadvantage. As a result, the Japanese government started reducing the “drug lag” times, and drugs for ovarian cancer, as well as many diseases, have been developed and approved more quickly.
Since 2013, Smiley has participated in World Ovarian Cancer Day and in the awareness and educational events of the Globe-athon to End Women’s Cancers. And, in 2019, Smiley supported the Eriko Aotani Patient–Caregiver Symposium at the 2019 IGCS Global Meeting in Kyoto, which was an opportunity for many Japanese patients and supporting groups to enhance their knowledge of gynecological cancer.
Following are some of my past and present advocacy engagements:
2009-2014—Member of Institutional Review Board (IRB) and of Conflict of Interest Committee (COI) of Japanese Gynecologic Oncology Group (JGOG)
2009-present—Member of Institutional Review Board (IRB) of Gynecologic Oncology Trial and Investigation Consortium of North Kanto (GOTIC)
2011—Member of Ministry of Health, Labor and Welfare Council Committee, which considered revision of the Pharmaceutical Affairs Law
2012—External Member of Center for Cancer Control and Information Service of National Cancer Center
2014—Member of Ministry of Health, Labor and Welfare Council Committee, which considered measures against counterfeit medicines and designated medicines
2015-2020—Board Member of All Tohoku Clinical Trial Review and Audit Organization (ACTIVATO)
Through Smiley and other advocacy work, Miho will continue to initiate and participate in activities that benefit “all ovarian cancer patients,” knowing that such action will give patients reasons to Smile.
Last Updated:2024-04-24 更新者:片木美穂


卵巣がん体験者の会スマイリー代表 片木美穂 Miho Katagi

氏名    片木 美穂
ふりがな  かたぎ みほ
現在の所属 卵巣がん体験者の会スマイリー
現在の役職 代表


1992年3月 金蘭会高校卒業
1994年3月 金蘭短期大学国文科卒業


1994年4月 トランス・コスモス株式会社入社
1999年7月 トランス・コスモス株式会社退社
2006年9月 卵巣がん体験者の会スマイリー設立 代表(現任)
2015年4月 一般社団法人東北臨床研究審査機構理事
2019年6月 一般社団法人東北臨床研究審査機構理事(退任)
現在    大学(医学部・看護学部など)の非常勤講師






2011年:厚生労働省 厚生科学審議会医薬品等制度改正検討部会委員 
2014年:厚生労働省 偽造医薬品・指定薬物対策推進会議構成員
2021年:一般社団法人日本医療安全学会 インフォームドコンセント部会(現職)
2023年:一般社団法人日本医療安全学会 「民間療法」のあり方に関する検討部会委員(現職)
2024年:慶應義塾大学治験審査委員会 企業治験審査委員(現職)


2010年:日経Woman of the year「注目の人」
2019年:2019 IGCS Distinguished Advocacy Award


雑誌「Clinical Research Professionals」がん臨床試験と患者の視点 連載中(2008年12月〜)



大阪府大阪市出身、東京都三鷹市在住 1973年9月13日生まれ A型。夫と息子の3人家族。

スマイリーの提言により厚生労働省は2010 年 2 月,「医療上の必要性の高い未承認薬・適応外薬検討会議」を立ち上げ、学会や患者会から医薬品の開発要望を募集し検討することに。2020年 2 月の第 40 回の検討会議終了までに345 品目もの医薬品が「医療上の必要性が高い」と評価され開発へ前進している。ドラッグ・ラグ問題が重篤であった日本の薬事承認を一気に前進させた。